PDCD1 and melanoma: Depletion of Tregs in melanoma using anti-CD25 was shown to reverse the response to anti-PD1 in non-responders [79], while in mice bearing a mammary tumor, neoadjuvant immune checkpoint blockade (ICB) was shown to remodel the intratumoral immune landscape characterized by an increase in CD8+T cells and NK cells and sustained T-cell activation [80].